Skip to main
CI

Cigna (CI) Stock Forecast & Price Target

Cigna (CI) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Cigna Group is well-positioned to capitalize on the projected growth of the biosimilar market, anticipated to reach $100 billion by 2030, providing significant revenue opportunities through its expanded pharmacy benefit management capabilities. The company's ability to generate double-digit savings on GLP-1 medications for employer clients further enhances its value proposition in health insurance services. Additionally, the build-out of Evernorth is expected to provide economic resilience, offsetting potential earnings headwinds during economic downturns, thereby reinforcing a positive outlook on Cigna's financial performance.

Bears say

Cigna Group faces several fundamental risks that may negatively impact its financial outlook, including challenges in accurately pricing and managing healthcare cost trends and prolonged regulatory scrutiny of pharmacy benefit managers (PBMs). Additionally, there are concerns regarding slow biosimilar adoption and insufficient specialty drug penetration, which could hinder growth for its Evernorth segment, coupled with potential client losses due to market dynamics. The company's management also anticipates limited material client shifting and adoption of new business structures under ICHRA/CHOICE, indicating a risk of adverse effects on employee benefit offerings, further exacerbated by potential increases in unemployment affecting commercial membership.

Cigna (CI) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cigna (CI) Forecast

Analysts have given Cigna (CI) a Buy based on their latest research and market trends.

According to 18 analysts, Cigna (CI) has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $355.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $355.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cigna (CI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.